Lorlatinib 25 mg, 100 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 25 mg, 100 mg

Reference Brands: Lorbrena (USA)

Category: Oncology Cancer Care

Lorlatinib tablets, a third-generation ALK inhibitor for ALK-positive metastatic non-small cell lung cancer. For importers, distributors, cancer hospitals and oncology tender buyers.

Product Description:

Lorlatinib is a third-generation tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and ROS1. It was designed to stay active against many resistance mutations that defeat earlier ALK inhibitors and to penetrate the central nervous system, where ALK-positive lung cancer often spreads. This page covers 25 mg and 100 mg tablets. The 100 mg tablet gives the standard dose and the 25 mg tablet allows reductions.

Lorlatinib is used for ALK-positive metastatic non-small cell lung cancer, first-line or after other ALK inhibitors, depending on the local label. The usual dose is 100 mg once daily, with or without food. Raised cholesterol and triglycerides are very common, so lipids are monitored and lipid-lowering drugs are often added. Mood, cognitive and speech changes need watching. Other precautions are atrioventricular block, interstitial lung disease, hypertension and hyperglycaemia. Strong CYP3A inducers are contraindicated because of serious liver toxicity, and hormonal contraceptives may fail.

Sourcing notes. Lorlatinib is a prescription-only targeted anticancer medicine, often handled under hazardous-drug procedures. Film-coated tablets in blisters or bottles are kept at room temperature, with no cold chain. Where the destination is hot and humid, the stability package should cover zone IVb with adequate moisture protection. Request a CTD or ACTD dossier, a CoA per batch with related substances, the GMP certificate and a CoPP. For generics, ask for bioequivalence and solid-form data. Patent and exclusivity status differ by market and must be checked before ordering.